Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Ultragenyx proposes to acquire Dimension Therapeutics By PBR Staff Writer
Ultragenyx Pharmaceutical has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics for $5.50 per share, or approximately $138m, in cash at close to be effectuated via a tender offer.
Drug Research > Drug Discovery & Development > News
Mustang Bio announces expansion of CAR T pipeline into CD20-directed immunotherapies Mustang Bio, a Fortress Biotech company, has announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.
Drug Research > Drug Discovery & Development > News BMS to use Halozyme’s Enhanze technology to develop immuno-oncology medicines By PBR Staff Writer
Bristol-Myers Squibb (BMS) has partnered with Halozyme Therapeutics for the development of immuno-oncology medicines.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Mustang Bio announces expansion of CAR T pipeline into CD20-directed immunotherapies
Mustang Bio, a Fortress Biotech company, has announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.
Drug Research > Drug Discovery & Development > News
BMS to use Halozyme’s Enhanze technology to develop immuno-oncology medicines
By PBR Staff Writer
Bristol-Myers Squibb (BMS) has partnered with Halozyme Therapeutics for the development of immuno-oncology medicines.
Drug Research > Drug Discovery & Development > News
Berkeley Lights, Bayer partner for cell line development and antibody discovery
Berkeley Lights (BLI), a company dedicated to bringing to market transformational platforms for bio-pharmaceutical processes, has announced a strategic project with Bayer, focused on the innovation and acceleration of cell line development, antibody discovery, and research.
Drug Research > Drug Discovery & Development > News
Inotek Pharmaceuticals announces merger deal with Rocket Pharmaceuticals
Inotek Pharmaceuticals announced that it has entered into a definitive merger agreement with US-based gene therapy company Rocket Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI
Summit Therapeutics announces that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has awarded Summit a contract worth up to $62m.
Drug Research > Drug Discovery & Development > News
HitGen, Takeda enter DNA-encoded library based drug discovery research collaboration
HitGen announced that the company has entered into a research collaboration with Takeda Pharmaceutical Company to discover novel small molecule leads for multiple targets in Takeda’s therapeutic areas of interest.
Drug Research > Drug Discovery & Development > News
Janssen scraps hepatitis C development program
By PBR Staff Writer
Janssen Sciences Ireland UC has scrapped its ongoing hepatitis C development program citing the growing number of therapies available for treating the disease effectively.
Drug Research > Drug Discovery & Development > News
Boehringer Ingelheim, Gubra to develop next generation obesity treatments
Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests